Search results for: Market Access

Competition through Innovation, Innovation through Competition

1 November 1998

…the multinational pharmaceutical industry to spend too much time, effort and money on ‘me-too’ research, as well as on research for line extensions of already marketed drugs’ (Wastila et al.,…

Cell & Gene Therapy

…and reimbursement strategies. Moreover, health economics contributes significantly to market access and equity. It addresses the challenges of ensuring broader patient access by examining pricing mechanisms and identifying ways to…

Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics

16 January 2024

…PMCID: PMC8234425.  Årdal et al., 2023. A Pan-EU/EEA Pull Incentive for Antimicrobial Innovation and Access. DRIVE-AB Policy Brief. Available at: https://drive-ab.eu/news/drive-ab-policy-brief-a-pan-eu-eea-pull-incentive-for-antimicrobial-innovation-and-access/  Brassel S., Firth I., Oliver E., Hampson, G., Towse A….

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

1 March 2017

The European Commission’s (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening diseases. Marketing authorisation granted…

Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals

1 September 2020

…a fair, value-based, price. How do we define fair access? This paper from ICER and OHE authors develops a fair access framework, proposing Ethical Goals for Access and Fair Design…

Paul Catchpole

11 December 2023

…market access, the Cancer Drugs Fund, Innovative Medicines Fund, biosimilar medicines, EAMS, ILAP and the Accelerated Access Collaborative. He has led the work on shaping and evolving value, access and…

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

17 March 2020

…by volume, and in developing country markets generic products dominate by both volume and value. In generic markets, patents have expired and we do not need price differentials to provide…

Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance

16 May 2017

…market entry rewards of US$1 billion per product. The market entry rewards proposed by O’Neill and GUARD of US$1 billion per product are too low to stimulate discovery and development…

Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries

29 October 2019

…“the most market-oriented health care systems anywhere in the industrialized world [2].” However, new analysis [3] by OHE finds that the countries that have been proposed as market-based instead “differ…